Oncternal Therapeutics, Inc.


8.6 (USD) • At close May 20, 2024
Bedrijfsnaam Oncternal Therapeutics, Inc.
Symbool ONCT
Munteenheid USD
Prijs 8.6
Beurswaarde 25,452,990
Dividendpercentage 0%
52-weken bereik 5.57 - 13.2
Industrie Biotechnology
Sector Healthcare
CEO Dr. James B. Breitmeyer M.D., Ph.D.
Website https://www.oncternal.com

An error occurred while fetching data.

Over Oncternal Therapeutics, Inc.

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of

Vergelijkbare Aandelen

Corbus Pharmaceuticals Holdings, Inc. logo

Corbus Pharmaceuticals Holdings, Inc.


48.55 USD

Biomerica, Inc. logo

Biomerica, Inc.


0.661 USD

Terns Pharmaceuticals, Inc. logo

Terns Pharmaceuticals, Inc.


6.25 USD

Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc.


3.27 USD

AVROBIO, Inc. logo



1.39 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)